Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
life sciences
national blog main
4
×
alnylam pharmaceuticals
aminolevulinic acid
clinical trials
deals
drugs
givosiran
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
biontech
biopharma
biotech
boehringer ingelheim
curevac
duchenne
eli lilly
europe blog main
europe top stories
fda
infectious diseases
john shiver
licensing
m&a
moderna therapeutics
mrna
muscular dystrophy
national top stories
new york blog main
new york top stories
onpattro
patisiran
paul matteis
roche
What
rna
4
×
second
4
×
medicine
alnylam
approval
deal
drug
fda
interference
new
pharmaceuticals
rnai
seek
speedy
ago
bets
betting
billion
bio
biopharma
cancer
cleared
comes
companies
cut
data
date
duchenne
effective
enticed
evidence
far
gene
hasn’t
historic
indicated
latest
market
medicines
messenger
Language
unset
Current search:
rna
×
second
×
" national blog main "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines